GlassScriptPhysician profile
Brian C Fellows
NPI 1548211659
$10,488.88
in general payments reported to CMS, 2019-2025
45 companies · $3,472 in 2025
The $3,472 reported for 2025 was more than what 98% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $136 · 2023: $3,083 · 2024: $3,799 · 2025: $3,472.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $10K · Education: $79.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,273.00 |
| Education | $79.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,585.69 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $808.01 | 2023-2025 | Airsupra, Breztri, Farxiga |
| Otsuka America Pharmaceutical, INC. | $656.36 | 2023-2025 | Rexulti, Abilify Maintena, Jynarque |
| Boehringer Ingelheim Pharmaceuticals, INC. | $581.17 | 2022-2025 | Jardiance, Synjardy, Tradjenta |
| Pfizer INC. | $553.25 | 2023-2025 | |
| Glaxosmithkline, LLC. | $484.37 | 2023-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Novo Nordisk INC | $473.85 | 2022-2025 | Rybelsus, Ozempic |
| Sumitomo Pharma America, INC. | $447.23 | 2023-2025 | Gemtesa |
| Lilly USA, LLC | $433.67 | 2023-2025 | Jardiance, Mounjaro, Zepbound |
| Lundbeck LLC | $382.86 | 2023-2025 | Rexulti, Brintellix |
| Bayer Healthcare Pharmaceuticals INC. | $355.94 | 2023-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $326.45 | 2023-2025 | Xifaxan |
| Teva Pharmaceuticals USA, INC. | $280.73 | 2022-2025 | Austedo Xr, Uzedy, Austedo Xr |
| Neurocrine Biosciences, INC. | $279.72 | 2024-2025 | Ingrezza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $274.88 | 2023-2025 | Caplyta |
Show all 45 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $253.35 | 2023-2025 | Veozah, Myrbetriq |
| Amgen INC. | $207.74 | 2022-2025 | Repatha, Otezla, Otezla |
| Alkermes, INC. | $196.19 | 2023-2025 | Aristada, Lybalvi |
| Mylan Specialty L.P. | $192.18 | 2023-2024 | Yupelri |
| Janssen Pharmaceuticals, INC | $184.98 | 2023-2024 | Xarelto |
| Novartis Pharmaceuticals Corporation | $158.61 | 2023-2024 | |
| Phathom Pharmaceuticals, INC. | $155.60 | 2024-2025 | Voquezna |
| Exact Sciences Corporation | $136.79 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| E.R. Squibb & Sons, L.L.C. | $133.89 | 2023-2025 | Eliquis, Camzyos |
| Xeris Pharmaceuticals, INC. | $105.84 | 2023-2024 | Gvoke Hypopen |
| Scilex Pharmaceuticals INC. | $93.50 | 2022-2024 | Ztlido |
| Idorsia Pharmaceuticals US INC | $93.30 | 2022-2023 | Quviviq |
| Shield Therapeutics INC | $65.97 | 2023-2024 | Accrufer |
| Indivior INC. | $62.78 | 2025 | Sublocade |
| Sk Life Science, INC. | $57.92 | 2025 | |
| Abbott Laboratories | $53.98 | 2023-2025 | Freestyle Libre 3 |
| Merck Sharp & Dohme LLC | $50.75 | 2023 | Belsomra, Steglatro |
| Corium, LLC | $49.87 | 2023 | Azstarys |
| Corcept Therapeutics | $44.57 | 2025 | Korlym |
| Viatris Specialty LLC | $36.11 | 2025 | Yupelri |
| Eisai INC. | $35.78 | 2025 | |
| Biogen, INC. | $28.32 | 2025 | Zurzuvae |
| Baxter Healthcare | $27.72 | 2025 | Hillrom - Carnation Ambulatory Monitor |
| Ardelyx, INC. | $25.69 | 2023 | Ibsrela |
| Cequr Corporation | $25.42 | 2025 | Cequr Simplicity |
| Valinor Pharma, LLC | $21.95 | 2023 | Movantik |
| Medtronic, INC. | $18.26 | 2025 | Venaseal |
| Lucid Diagnostics INC. | $18.09 | 2024 | |
| Siemens Medical Solutions USA, INC. | $15.57 | 2024 | Dca Systems Hemoglobin A1c Reagent Kit |
| Organon LLC | $13.98 | 2025 | Vtama |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Fellows listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.